9HJQ | pdb_00009hjq

ROCK2 bound with TDI01


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 9HJQ

This is version 1.1 of the entry. See complete history

Literature

Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.

Hu, Y.Yang, B.Xiao, C.Yang, X.Zhang, H.Yang, P.Du, X.Zhang, G.Liang, B.Bai, N.Zhang, D.Wu, D.Luo, Q.Teng, Y.Chen, Y.Guo, Z.Zhao, C.Ye, T.Chai, D.Qi, X.Zhong, W.Chen, J.Dong, H.Gao, J.He, H.Chang, J.Li, X.Peng, L.Rafii, S.Friedman, S.L.Yi, C.Cai, Y.Zhao, Y.Wang, H.Wang, C.Cao, Z.Ding, B.S.

(2026) Cell 189: 2663-2683.e26

  • DOI: https://doi.org/10.1016/j.cell.2026.02.001
  • Primary Citation Related Structures: 
    9HJQ

  • PubMed Abstract: 

    Liver fibrosis is a prominent pathological process contributing to death from hepatic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). There is limited treatment for liver fibrosis. Here, we find that upregulation of Rho-associated coiled-coil containing kinase 2 (ROCK2) in liver endothelial cells (ECs) and perivascular hepatic stellate cells (HSCs) causes vascular niche dysfunction and triggers pro-fibrotic angiocrine signaling. Based on the vascular druggable target ROCK2, we developed its selective inhibitor showing anti-fibrotic potency in preclinical models and human patients. The ROCK2-selective inhibitor TDI01 restored vascular phenotype and alleviated fibrosis in rodent and minipig MASH models. A phase 1 clinical trial (ChiCTR2200058868) of TDI01 demonstrated its favorable pharmacokinetics and safety in humans. An extended clinical trial (ChiCTR2400082056) showed a trend toward reducing liver fibrosis in five of six patients after TDI01 treatment. Thus, we discover vascular ROCK2 as a pro-fibrotic target, and development of an inhibitor selectively targeting angiocrine ROCK2 may provide a treatment of liver fibrosis in human patients.


  • Organizational Affiliation
    • Key Lab of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Respiratory Health and Multimorbidity, State Key Laboratory of Biotherapy, Division of Abdominal Tumor Multimodality Treatment, Division of Gastrointestinal Surgery, Department of Radiology, Center of Infectious Diseases, West China Second Hospital, West China School of Basic Medical Sciences & Forensic Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.

Macromolecule Content 

  • Total Structure Weight: 92.83 kDa 
  • Atom Count: 5,456 
  • Modeled Residue Count: 658 
  • Deposited Residue Count: 802 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Rho-associated protein kinase 2
A, B
401Homo sapiensMutation(s): 0 
Gene Names: ROCK2KIAA0619
EC: 2.7.11.1 (PDB Primary Data), 2.7.11.39 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for O75116 (Homo sapiens)
Explore O75116 
Go to UniProtKB:  O75116
GTEx:  ENSG00000134318 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO75116
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1IVI
(Subject of Investigation/LOI)

Query on A1IVI



Download:Ideal Coordinates CCD File
C [auth A],
D [auth B]
[3,3-bis(fluoranyl)azetidin-1-yl]-[1-methyl-6-[4-[[4-(1~{H}-pyrazol-4-yl)phenyl]amino]pyrimidin-2-yl]indol-2-yl]methanone
C26 H21 F2 N7 O
GWMOTZHLJFWMIZ-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
MODEL REFINEMENTPHENIX

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Natural Science Foundation of China (NSFC)China--

Revision History  (Full details and data files)

  • Version 1.0: 2026-06-17
    Type: Initial release
  • Version 1.1: 2026-07-01
    Changes: Data collection, Database references